For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 17,197 | 17,491 | 14,969 | 20,276 |
| General and administrative | 3,984 | 3,993 | 4,101 | 4,457 |
| Total operating expenses | 21,181 | 21,484 | 19,070 | 24,733 |
| Loss from operations | -21,181 | - | -19,070 | -24,733 |
| Other income, net | 1,118 | 540 | 1,047 | 1,224 |
| Change in fair value of warrant liabilities | 18,962 | -10,506 | -564 | -12,293 |
| Loss before income taxes | - | -10,438* | - | - |
| Provision for income taxes | - | 9* | - | - |
| Net loss | -39,025 | -10,447 | -17,459 | -11,216 |
| Basic EPS | -0.33 | -0.109 | -0.21 | -0.13 |
| Diluted EPS | -0.33 | -0.109 | -0.21 | -0.13 |
| Basic Average Shares | 112,424,211 | 95,906,085 | 77,156,068 | 77,156,068 |
| Diluted Average Shares | 112,424,211 | 95,906,085 | 77,156,068 | 77,156,068 |
Eledon Pharmaceuticals, Inc. (ELDN)
Eledon Pharmaceuticals, Inc. (ELDN)